Cyclophosphamide Tablets and Urinary tract obstruction
Result of checking the interaction of drug Cyclophosphamide Tablets and disease Urinary tract obstruction for safety when used together.
When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.
Consumer:The use of cyclophosphamide is contraindicated in patients with any urinary outflow obstruction. Before treatment initiation, urinary obstruction should be excluded or corrected. Hemorrhagic cystitis, pyelitis, and hematuria have been reported during cyclophosphamide therapy. Adequate hydration and use of a prophylactic agent such as mesna prior to each course of cyclophosphamide therapy reduces bladder irritation and hematuria. Therapy with cyclophosphamide should be administered cautiously in patients with or predisposed to cystitis, including patients with active urinary infections. Treatment should be discontinued if there is sign of urotoxicity as hemorrhagic cystitis, bladder ulceration, necrosis, fibrosis, contractures, etc. Urinary sediment should be checked regularly for presence or erythrocytes and other signs of toxicity.
- "Product Information. Cytoxan (cyclophosphamide)." Bristol-Myers Squibb, Princeton, NJ.
Generic Name: cyclophosphamide
Brand Name: Cytoxan, Neosar, Cytoxan Lyophilized
Synonyms: Cyclophosphamide (oral and injection), Cyclophosphamide